‘Revolutionary’ liquid sickle cell treatment unveiled
PharmaTimes | October 25, 2019
Nova Laboratories has announced details of its “revolutionary” new liquid formation of hydroxycarbamide for sickle cell disease. The product in question, Xromi (hydroxycarbamide), was granted a license by the European Medicines Agency (EMA) in July 2019, and represents a significant evolution of solid dosage forms of the drug that have been used in the treatment of sickle cell disease since the 1990s. The new liquid formation makes administering the drug to children as young as two-years-old significantly easier, and will enable doctors to personalise doses for young children. The formation, which was announced at the Annual Sickle Cell and Thalassaemia conference in London, has been in development for four years, with investments in the region of £5.2m in product development and trials. The company has confirmed that new formation will be available on prescription only in the UK, EU and the Middle East through sickle cell disease healthcare specialists, but promises that worldwide availability is planned.